Earnings call transcript: Lexin Q2 2026 profit falls as Q3 loss looms

Lexin reported Q2 2026 revenue of RMB 3.19B (roughly flat) but net income fell 49.7% sequentially to RMB 101M, as tightening funding conditions led to credit costs rising 9.6% to RMB 1.4B and loan origination volume dropping 4.3% to RMB 55.43B. The company guided for a Q3 net loss, expecting lower revenue and higher provisions amid further funding-supply contraction and rising delinquency. Shares fell 17.54% to $0.973 premarket, reflecting investor focus on the Q3 loss outlook rather than the Q2 print. Lexin also shifted dividends from semiannual to annual to preserve liquidity and said it is expanding AI usage to drive further operating-cost reductions.

Analysis

This is less an earnings miss than a funding-franchise reset. When a facilitator’s upstream capital gets scarcer, every extra turn of tightening hits twice: originations fall first, then provisions rise as the platform deliberately shrinks risk rather than chase volume. That makes the equity a timing bet on wholesale confidence, not a clean valuation story; cheap P/B is irrelevant if ROE stays below cost of equity for multiple quarters.

The second-order damage should spread to other partner-funded consumer credit models in China: wider funding spreads, stricter underwriting, lower marketing intensity, and more rapid industry consolidation as weaker platforms lose access before they fail operationally. The likely relative winners are capital-light fee businesses and lenders with captive funding or stronger institutional trust; within the provided list, CICC is a more defensible macro-financial proxy than LX, but the main point is that sentiment spillover can lift all China financial risk premia even where economics are not directly exposed.

Contrarian take: the market may be overpricing solvency risk and underpricing duration risk. If funding opens even modestly in the next 1-2 quarters, LX can re-rate violently because expectations are already depressed; if not, the stock remains a melting ice cube as dividends stay paused and reserve coverage absorbs cash flow. The falsifiers are a visible reopening of funding partners, a smaller-than-feared Q3 loss, or evidence that delinquency/provision trends have peaked.

Key Decisions for Investors

• Short LX on any relief rally back toward $1.05-$1.10 over the next 2-6 weeks; thesis breaks if the stock reclaims $1.20 on improving funding commentary or a materially better-than-feared Q3 update.
• If options/liquidity are available, prefer a defined-risk LX put spread into the Q3 print rather than outright puts; the name is too low-priced for sloppy delta exposure and borrow can become crowded.
• Relative-value idea: short LX / long CICC as a China financials pair trade for the next 1-3 months, betting that funding-shock sensitivity stays much higher at LX than at a more diversified capital-market intermediary.
• Do not catch the falling knife here: wait for evidence that partner funding is normalizing before considering a long; absence of that data means this is a watchlist name, not an entry.
• Falsifier to monitor: if management’s next update shows funding supply reopening and Q3 losses are smaller than implied, cover shorts quickly—the equity could squeeze hard from deeply distressed positioning.